Compare Stocks: PHAT, GPCR, MLYS, and SUPN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$35.00 -0.3%	$47.79	$22.70 ▼ $94.90	$2.44B	-1.45	1.04 million shs	1.55 million shs
MLYS Mineralys Therapeutics	$28.02 +0.1%	$27.12	$22.30 ▼ $47.65	$2.47B	0.68	1.13 million shs	3.79 million shs
PHAT Phathom Pharmaceuticals	$7.48 -3.5%	$9.45	$7.47 ▼ $18.31	$626.98M	0.51	1.08 million shs	1.79 million shs
SUPN Supernus Pharmaceuticals	$42.00 -2.1%	$45.51	$40.51 ▼ $59.68	$2.50B	0.56	545,266 shs	1.18 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	-0.28%	-9.47%	-35.34%	-21.37%	+61.66%
MLYS Mineralys Therapeutics	+0.14%	-0.64%	+3.97%	+13.76%	-24.86%
PHAT Phathom Pharmaceuticals	-3.48%	-10.53%	-19.74%	-31.25%	-32.00%
SUPN Supernus Pharmaceuticals	-2.14%	+0.86%	-13.47%	-5.36%	-6.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$35.00 -0.3%	$47.79	$22.70 ▼ $94.90	$2.44B	-1.45	1.04 million shs	1.55 million shs
MLYS Mineralys Therapeutics	$28.02 +0.1%	$27.12	$22.30 ▼ $47.65	$2.47B	0.68	1.13 million shs	3.79 million shs
PHAT Phathom Pharmaceuticals	$7.48 -3.5%	$9.45	$7.47 ▼ $18.31	$626.98M	0.51	1.08 million shs	1.79 million shs
SUPN Supernus Pharmaceuticals	$42.00 -2.1%	$45.51	$40.51 ▼ $59.68	$2.50B	0.56	545,266 shs	1.18 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	-0.28%	-9.47%	-35.34%	-21.37%	+61.66%
MLYS Mineralys Therapeutics	+0.14%	-0.64%	+3.97%	+13.76%	-24.86%
PHAT Phathom Pharmaceuticals	-3.48%	-10.53%	-19.74%	-31.25%	-32.00%
SUPN Supernus Pharmaceuticals	-2.14%	+0.86%	-13.47%	-5.36%	-6.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GPCR Structure Therapeutics	2.82	Moderate Buy	$110.91	216.88% Upside
MLYS Mineralys Therapeutics	2.50	Moderate Buy	$48.80	74.16% Upside
PHAT Phathom Pharmaceuticals	2.78	Moderate Buy	$21.25	184.09% Upside
SUPN Supernus Pharmaceuticals	2.43	Hold	$62.83	49.60% Upside

Current Analyst Ratings Breakdown

Latest PHAT, GPCR, MLYS, and SUPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	MLYS Mineralys Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/9/2026	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2026	PHAT Phathom Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$10.00
9/9/2026	GPCR Structure Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$110.00
9/9/2026	PHAT Phathom Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$10.00
9/4/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2026	PHAT Phathom Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$18.00 ➝ $14.00
8/13/2026	MLYS Mineralys Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/7/2026	GPCR Structure Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$111.00
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$100.00 ➝ $97.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$24.99 per share	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$8.17 per share	N/A
PHAT Phathom Pharmaceuticals	$175.11M	3.46	N/A	N/A	($6.14) per share	-1.22
SUPN Supernus Pharmaceuticals	$830.44M	2.94	$3.69 per share	11.37	$18.52 per share	2.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GPCR Structure Therapeutics	-$141.20M	-$1.00	N/A	N/A	N/A	N/A	-25.56%	-24.31%	11/5/2026 (Estimated)
MLYS Mineralys Therapeutics	-$154.65M	-$4.24	N/A	N/A	N/A	N/A	-57.97%	-54.15%	11/9/2026 (Estimated)
PHAT Phathom Pharmaceuticals	-$221.25M	-$1.28	N/A	6.45	N/A	-41.34%	N/A	-20.81%	10/29/2026 (Estimated)
SUPN Supernus Pharmaceuticals	-$38.55M	-$1.92	N/A	10.88	0.79	-13.23%	11.13%	8.10%	11/3/2026 (Estimated)

Latest PHAT, GPCR, MLYS, and SUPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	MLYS Mineralys Therapeutics	-$0.5486	-$2.85	-$2.3014	-$2.85	N/A	N/A
8/6/2026	Q2 2026	GPCR Structure Therapeutics	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
8/3/2026	Q2 2026 & Merger	SUPN Supernus Pharmaceuticals	$0.4225	-$1.01	-$1.4325	-$1.01	$205.31 million	$219.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GPCR Structure Therapeutics	N/A	20.75	20.75
MLYS Mineralys Therapeutics	0.18	34.46	34.46
PHAT Phathom Pharmaceuticals	N/A	1.92	1.87
SUPN Supernus Pharmaceuticals	N/A	2.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GPCR Structure Therapeutics	91.78%
MLYS Mineralys Therapeutics	84.46%
PHAT Phathom Pharmaceuticals	99.01%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
GPCR Structure Therapeutics	5.50%
MLYS Mineralys Therapeutics	18.94%
PHAT Phathom Pharmaceuticals	9.33%
SUPN Supernus Pharmaceuticals	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GPCR Structure Therapeutics	281	69.62 million	65.79 million	Optionable
MLYS Mineralys Therapeutics	76	88.41 million	71.66 million	Optionable
PHAT Phathom Pharmaceuticals	371	80.90 million	73.35 million	Optionable
SUPN Supernus Pharmaceuticals	778	58.22 million	53.28 million	Optionable

PHAT, GPCR, MLYS, and SUPN Headlines

Recent News About These Companies

Engineers Gate Manager LP Makes New $1.12 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

September 19 at 3:13 AM | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Average Recommendation of "Hold" from Brokerages

September 18 at 6:13 AM | marketbeat.com

Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing

September 17 at 7:31 AM | quiverquant.comQ

Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month Low - What's Next?

September 15, 2026 | marketbeat.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 1-Year Low - Time to Sell?

September 8, 2026 | marketbeat.com

Jupiter Topco LLC Buys Shares of 23,254 Supernus Pharmaceuticals, Inc. $SUPN

September 6, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Invests $1.30 Million in Supernus Pharmaceuticals, Inc. $SUPN

September 5, 2026 | marketbeat.com

Legal & General Group Plc Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

September 3, 2026 | marketbeat.com

Supernus Pharmaceuticals to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

Bank of New York Mellon Corp Makes New $17.55 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

September 1, 2026 | marketbeat.com

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

August 31, 2026 | globenewswire.com

156,422 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Man Group plc

August 30, 2026 | marketbeat.com

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 29, 2026 | businesswire.com

Freestone Grove Partners LP Invests $14.72 Million in Supernus Pharmaceuticals, Inc. $SUPN

August 28, 2026 | marketbeat.com

91,070 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by Algert Global LLC

August 28, 2026 | marketbeat.com

25,858 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by PDT Partners LLC

August 27, 2026 | marketbeat.com

Deutsche Bank AG Takes $2.96 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

August 27, 2026 | marketbeat.com

Elmind Capital LP Invests $3.26 Billion in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

BlackRock Inc. Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New $1.29 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

Quantbot Technologies LP Purchases Shares of 47,700 Supernus Pharmaceuticals, Inc. $SUPN

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT, GPCR, MLYS, and SUPN Company Descriptions

Structure Therapeutics NASDAQ:GPCR

$35.00 -0.10 (-0.28%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$34.79 -0.21 (-0.61%)

As of 09/18/2026 07:55 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Mineralys Therapeutics NASDAQ:MLYS

$28.02 +0.04 (+0.14%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$27.79 -0.23 (-0.82%)

As of 09/18/2026 07:56 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Phathom Pharmaceuticals NASDAQ:PHAT

$7.48 -0.27 (-3.48%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.52 +0.04 (+0.53%)

As of 09/18/2026 07:30 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Supernus Pharmaceuticals NASDAQ:SUPN

$42.00 -0.92 (-2.14%)

As of 09/18/2026 04:00 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAT, GPCR, MLYS, and SUPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAT, GPCR, MLYS, and SUPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAT, GPCR, MLYS, and SUPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT, GPCR, MLYS, and SUPN Company Descriptions

Structure Therapeutics NASDAQ:GPCR

Mineralys Therapeutics NASDAQ:MLYS

Phathom Pharmaceuticals NASDAQ:PHAT

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAT, GPCR, MLYS, and SUPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAT, GPCR, MLYS, and SUPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAT, GPCR, MLYS, and SUPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT, GPCR, MLYS, and SUPN Company Descriptions

Structure Therapeutics NASDAQ:GPCR

Mineralys Therapeutics NASDAQ:MLYS

Phathom Pharmaceuticals NASDAQ:PHAT

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools